Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002458 · ClinicalTrials.gov registry record · Phase 2
Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002458: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00002458 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002458, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody in treating children with metastatic neuroblastoma in second remission.
Interventions
- BIOLOGICAL monoclonal antibody 3F8
Trial Details
| Field | Value |
|---|---|
| Start Date | 1987-11 |
| Est. Completion | 2001-09 |
| Phase | Phase 2 |
What the finished NCT00002458 record still lists
NCT00002458 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which monoclonal antibody 3F8 is the first listed.
NCT00002458 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002458 about?
NCT00002458 is a clinical study titled "Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody in treating children with metastatic neuroblastoma in second remission.
What is the current status of trial NCT00002458?
This trial is currently completed. It is a Phase 2 study. The study started on 1987-11. Estimated completion is 2001-09.
What interventions are being tested in trial NCT00002458?
The interventions under investigation include: monoclonal antibody 3F8 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002458?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia